Role of size of drug delivery carriers for pulmonary and intravenous administration with emphasis on cancer therapeutics and lung-targeted drug delivery

RSC Advances ◽  
2014 ◽  
Vol 4 (62) ◽  
pp. 32673-32689 ◽  
Author(s):  
Chetna Dhand ◽  
Molamma P. Prabhakaran ◽  
Roger W. Beuerman ◽  
R. Lakshminarayanan ◽  
Neeraj Dwivedi ◽  
...  
Keyword(s):  
Drug Delivery ◽  
Drug Delivery System ◽  
Delivery System ◽  
Intravenous Administration ◽  
Targeted Drug Delivery ◽  
Cancer Therapeutics ◽  
Drug Carriers ◽  
Design Parameters ◽  
Targeted Drug

The design of a drug delivery system and the fabrication of efficient, successful, and targeted drug carriers are two separate issues that require slightly different design parameters.

scholarly journals ADAM9-Responsive Mesoporous Silica Nanoparticles for Targeted Drug Delivery in Pancreatic Cancer

Cancers ◽  
2021 ◽  
Vol 13 (13) ◽  
pp. 3321
Author(s):  
Etienne J. Slapak ◽  
Lily Kong ◽  
Mouad el Mandili ◽  
Rienk Nieuwland ◽  
Alexander Kros ◽  
...  
Keyword(s):  
Drug Delivery ◽  
Mesoporous Silica ◽  
Silica Nanoparticles ◽  
Conditioned Medium ◽  
Drug Delivery System ◽  
Delivery System ◽  
Targeted Drug Delivery ◽  
Mesoporous Silica Nanoparticles ◽  
Pdac Cell ◽  
Targeted Drug

Pancreatic ductal adenocarcinoma (PDAC) has the worst survival rate of all cancers. This poor prognosis results from the lack of efficient systemic treatment regimens, demanding high-dose chemotherapy that causes severe side effects. To overcome dose-dependent toxicities, we explored the efficacy of targeted drug delivery using a protease-dependent drug-release system. To this end, we developed a PDAC-specific drug delivery system based on mesoporous silica nanoparticles (MSN) functionalized with an avidin–biotin gatekeeper system containing a protease linker that is specifically cleaved by tumor cells. Bioinformatic analysis identified ADAM9 as a PDAC-enriched protease, and PDAC cell-derived conditioned medium efficiently cleaved protease linkers containing ADAM9 substrates. Cleavage was PDAC specific as conditioned medium from leukocytes was unable to cleave the ADAM9 substrate. Protease linker-functionalized MSNs were efficiently capped with avidin, and cap removal was confirmed to occur in the presence of PDAC cell-derived ADAM9. Subsequent treatment of PDAC cells in vitro with paclitaxel-loaded MSNs indeed showed high cytotoxicity, whereas no cell death was observed in white blood cell-derived cell lines, confirming efficacy of the nanoparticle-mediated drug delivery system. Taken together, this research introduces a novel ADAM9-responsive, protease-dependent, drug delivery system for PDAC as a promising tool to reduce the cytotoxicity of systemic chemotherapy.

Corrigendum to: Establishment and In Vitro Evaluation of Porous Ion-Responsive Targeted Drug Delivery System. Protein & Peptide Letters, volume 27(11), (2020).

2021 ◽  
Vol 28 (3) ◽  
pp. 359-359
Author(s):  
Hongfei Liu ◽  
Jie Zhu ◽  
Pengyue Bao ◽  
Yueping Ding ◽  
Jiapeng Wang ◽  
...  
Keyword(s):  
Drug Delivery ◽  
Drug Delivery System ◽  
Delivery System ◽  
Targeted Drug Delivery ◽  
Electronic Version ◽  
In Vitro Evaluation ◽  
Corrected Version ◽  
Targeted Drug ◽  
Targeted Drug Delivery System

The authors are regretful for submitting and approving the publication of incorrect Figure 4 in this article. Below is the corrected version along with the revised caption. The electronic version of the article has already been corrected.

scholarly journals A simple synthesis of a targeted drug delivery system with enhanced cytotoxicity

2011 ◽  
Vol 47 (30) ◽  
pp. 8530 ◽  
Author(s):  
Sanjib Bhattacharyya ◽  
Maria Gonzalez ◽  
J. David Robertson ◽  
Resham Bhattacharya ◽  
Priyabrata Mukherjee
Keyword(s):  
Drug Delivery ◽  
Drug Delivery System ◽  
Delivery System ◽  
Targeted Drug Delivery ◽  
Simple Synthesis ◽  
Targeted Drug ◽  
Targeted Drug Delivery System
Sign in / Sign up

Export Citation Format

Share Document